- 08:04 PM November 27: Events to watch out for
- 07:18 PM Govt deeply concerned about rising prices: Pranab ...
- 06:46 PM MFs net buy Rs 158 cr in equities on Nov 25
- 06:38 PM FIIs net buy Rs 65.20 cr in equities on Nov 25
- 06:27 PM Nirmal Bang's after market report
- 06:21 PM Karvy negative on telecom sector
- 06:20 PM Support for rupee around 46.20/46.10: Commtrendz
- 06:08 PM Nirmal Bang's evening guide on commodity
- 06:04 PM Air India shelves lowcost carrier plans; peers ral...
- 05:57 PM Surging food prices may prompt RBI action


Foreign currency convertible bonds or FCCBs that helped Indian pharma companies in growth and acquisitions during the bull run, have become a serious concern post the slide in their share prices.
Here is a transcript of Sriram Iyer’s comments on CNBC-TV18. Also watch the accompanying video.
Maturing FCCBs have posed problems across sectors and Indian pharma is no exception. According to estimates, India Inc issued close to USD 20 billion of FCCBs in the last few years.
Burden of FCCB:
With conversion prices soaring well above the current share value; companies will either have to look for fresh debt at higher interest rates or reset the conversion clause diluting promoter holdings.
Pharma companies that had raised FCCBs recorded a notional forex related loss in their books. This year, Ranbaxy has booked losses to the tune of Rs 585 crore, Jubilant recorded Rs 282 crore, Aurobindo recorded Rs 159 crore, while Orchid and Wockhardt booked Rs 140 crore and Rs 112 crore respectively.
Redemption date, cash flow and share prices determine the depth of the problem for these companies. Experts say Wockhardt and Aurobindo Pharma top the list of vulnerability. The USD 110 million FCCB raised by Wockhardt is slated for conversion in September 2009 at Rs 486 against the current price of around Rs 95. It seems unlikely for its shares to rise to the conversion price and neither its cash flow generation for the next year appears very healthy.
Aurobindo's FCCBs mature in 2010-2011 and its current market price is a tenth of the set conversion price. Despite a strong performance in 2007, the company's shares rose up to about Rs 800, as against the set conversion price of rs.1014. Thanks to the huge capex incurred in the last couple of years, its cash flows have remained negative and the future looks as bleak.
Sun Pharma has already converted its fccbs while lupin's shares float higher than the conversion rate.
Experts believe that for Ranbaxy and Jubilant it may be a relatively easier ordeal.
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- 10 companies that MF managers love
- Why Gates, Buffett are not giving up on US economy

- Indian mkt to reach new highs in 2010: Roubini firm

- Ashwani Gujral's top five picks for today's trade

- Ganeshaspeaks: Market prediction for Nov 26
- Expert stock/sector picks in these markets

- Sensex ends 344 pts down; mkts see highest turnover ever
- India to sell $70 bn shares in 3 years: Morgan Stanley
- Mahindra Satyam to declare audited nos by June 2010

- Lanco Infra tying up funds for three power projects
Source: Business Line
- RIL units to get 20% of gas needs from D-6
Source: Business Line
- No need to ban cotton export, says Maran
Source: Business Line
- Karnataka hikes power tariff by 34.16 paise/unit
Source: Business Line











